《普拉格雷的生物转化,新型噻吩吡啶类抗血小板制剂,药理活性的代谢产物》由会员分享，可在线阅读，更多相关《普拉格雷的生物转化,新型噻吩吡啶类抗血小板制剂,药理活性的代谢产物（7页珍藏版）》请在金锄头文库上搜索。
1、Short CommunicationBiotransformation of Prasugrel, a Novel Thienopyridine Antiplatelet Agent, to the Pharmacologically Active MetaboliteReceived January 6, 2010; accepted February 26, 2010ABSTRACT:Prasugrel, a novel thienopyridine antiplatelet agent, undergoes rapid hydrolysis in vivo to a thiolacto
2、ne, R-95913, which is further converted to its thiol-containing, pharmacologically active metab- olite, R-138727, by oxidation via cytochromes P450 (P450). We trapped a sulfenic acid metabolite as a mixed disulfide with 2-nitro- 5-thiobenzoic acid in an incubation mixture containing the thiolac- ton
3、e R-95913, expressed CYP3A4, and NADPH. Further experi- ments investigated one possible mechanism for the conversion of the sulfenic acid to the active thiol metabolite in vitro. A mixeddisulfide form of R-138727 with glutathione was found to be a possible precursor of R-138727 in vitro when glutath
4、ione was present. The rate constant for the reduction of the glutathione conjugate of R-138727 to R-138727 was increased by addition of human liver cytosol to the human liver microsomes. Thus, one possible mechanism for the ultimate formation of R-138727 in vitro can be through formation of a sulfen
5、ic acid mediated by P450s followed possibly by a glutathione conjugation to a mixed disulfide and reduction of the disulfide to the active metabolite R-138727.Prasugrel Effient (Eli Lilly and Company, Indianapolis, IN) in the United States and Efient (Eli Lilly and Company) in the European Union, cl
6、opidogrel Plavix (Sanofi-Aventis, Paris, France)/Iscover (Bristol-Myers Squibb, New York, NY), and ticlopidine (Ticlid; Sanofi-Aventis) are thienopyridine antiplatelet agents. Prasugrel has been shown to reduce the rate of thrombotic cardiovascular events and stent thrombosis in patients with acute
7、coronary syndrome that are undergoing percutaneous coronary intervention (Wiviott et al., 2007) (Effient package insert). The thienopyridines are prodrugs that are converted in vivo to their pharmacologically active metabolites that possess a thiol group via a corresponding thiolactone metabolite (F
8、arid et al., 2010). However, with the exception of an oxidation step catalyzed by cytochrome P450 (Savi et al., 1994; Rehmel et al., 2006), the mechanism for the active metabolite formation from thienopyri- dines remained unknown until recently reported for ticlopidine and clopidogrel (Dansette et a
9、l., 2009). In the case of prasugrel, the active metabolite R-138727 was not detected when the thiolactone metabo- lite R-95913 was incubated with liver homogenates or microsomes in the absence of cofactors, but it was detected when NADPH and a reducing agent such as glutathione were added to the sys
10、tem (Kazui et al., 2000). A sulfenic acid, which is a likely intermediate for the activation of prasugrel, reacts readily with a thiol compound, typically glutathione in vivo, to yield a disulfide metabolite (Decker et al., 1991; Kassahun et al., 2001; Reddy et al., 2005; Dansette et al., 2009). The
11、 formed disulfide can be further reduced to provide a thiol- containing compound. The objective of this study is to investigate theinvolvement of a sulfenic acid and a glutathione conjugate of R-138727 in the in vitro production of prasugrels active metabolite (R-138727) from the thiolactone interme
12、diate (R-95913) (Fig. 1).Materials and MethodsMaterials. R-138727 (prasugrel active metabolite), glutathione conjugate of R-138727, and R-95913 (prasugrel thiolactone metabolite) were synthesized by Ube Industries, Ltd. (Ube, Japan). 5,5?-Dithio-bis(2-nitrobenzoic acid) (DTNB) and tris(carboxyethyl)
13、phosphine (TCEP), used as a reagent to reduce DTNB to 2-nitro-5-thiobenzoic acid (TNB), were purchased from Sigma- Aldrich (St. Louis, MO). Microsomes from insect cells that expressed CYP3A4 (cDNA-expressed CYP3A4) were purchased from Gentest Corpora- tion (Woburn, MA). All other chemicals and reage
14、nts were commercially available and were of the highest grade. Water was purified by using a Milli-Q purification system (Millipore Corporation, Billerica, MA). Preparation of TNB-R-138727 Disulfide. A mixed disulfide of R-138727 with TNB (TNB-R-138727 disulfide) was prepared by reacting R-138727 wi
15、th equimolar DTNB in an aqueous solution (Fig. 2) because the synthesis using the chemically unstable sulfenic acid-derivative of R-138727 and TNB was difficult to perform. After dilution of the reaction mixture with acetonitrile and after centrifugation, a 20-?l aliquot of the supernatant fraction
16、was directly injected onto a YMC-Pack ODS-A (A-312) column (150 mm ? 6.0 mm i.d., 5?m; YMC Co., Ltd., Kyoto, Japan), maintained at ambient temperature. A high-performance liquid chromatography (HPLC) analysis was performed by using a low-pressure gradient elution system that consisted of an L-7100 Intelligent Pump, a D-7500 Chromato-Integrator, and an L-7400S UV Detector (Hitachi, Ltd., Tokyo, Japan). The mobile phase, 30% (v/v) acetonitrile in water that contained 0.01% (v/v) trifluoroacet
